Short Term Price Target on Sanofi (SNY)

Sanofi (NYSE:SNY) : Average target price received by Sanofi (NYSE:SNY) is $55.5 with an expected standard deviation of $3.54. The most aggressive target on the stock is $58, whereas the most downbeat target is $53. 2 financial analysts are currently covering the stock.

Shares of Sanofi rose by 1.6% in the last five trading days and 1.73% for the last 4 weeks. Sanofi is up 8.13% in the last 3-month period. Year-to-Date the stock performance stands at 2.25%. Also, In a research note released to the investors, Barclays upgrades its rating on Sanofi (NYSE:SNY).The analysts at the brokerage house have a current rating of Overweight on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on May 12, 2016.

Sanofi (NYSE:SNY) : 3 brokerage houses believe that Sanofi (NYSE:SNY) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Sanofi (NYSE:SNY). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.8.

Sanofi (NYSE:SNY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $41.22 and $41.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $41.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $41.85, notching a gain of 1.43% for the day. The total traded volume was 3,386,768 . The stock had closed at $41.26 on the previous day.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.